Ilyang Pharmaceutical Co.,Ltd
Ilyang Pharmaceutical Co.,Ltd (KRX: 007570) is trading at ₩7,950.00, about ₹574 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 1.85% today. Ilyang Pharmaceutical is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩7,910.00
Today's high
₩8,100.00
52 week low
₩7,290.00
52 week high
₩16,240.00
007570 opened at ₩8,010.00, closed previously at ₩8,100.00, and has traded between ₩7,290.00 and ₩16,240.00 over the past 52 weeks.
About
Headquartered in Yongin, South Korea, Ilyang Pharmaceutical Co.,Ltd is a prominent pharmaceutical enterprise that has been operating since its establishment in 1946. The company, which was formerly known as Il-Yang Pharm. Ind. Co. until its renaming in May 1991, primarily conducts its business in South Korea. It develops and provides a comprehensive portfolio of medicines addressing various therapeutic areas, such as oncology, cardiovascular health, endocrine and metabolic conditions, women's health (including female hormone treatments and cheonjiyang), urology, ophthalmology, liver diseases, pain and inflammation, digestive system issues, dermatological complaints, and respiratory illnesses. Their pharmaceutical offerings also extend to nutrient infusions, neurological medications, antibiotics, antifungals, insecticides, and vaccines. In addition to medicinal products, Ilyang manufactures a range of consumer health items, including health drinks, dietary supplements, health foods, cosmetics, and other beverages. The company is also a producer of numerous pharmaceutical raw materials, specifically various aluminum and magnesium compounds. Ilyang Pharmaceutical has an international footprint, exporting its diverse product range to roughly 14 countries worldwide.
Key statistics
Avg. volume
63.90K
Market cap
₩142.50B
P/E Ratio
7.86
Price-to-sales ratio
0.51
Enterprise value
₩358.02B
Free cash flow yield
0.63%
Debt-to-equity ratio
0.41
Return on equity
2.91%
ROIC
0.67%
Beta
0.43
Dividend yield
1.95%
Last dividend
₩155.00
Financial overview
Revenue
₩272.24B
Earnings per share
₩375.42
Free cash flow
₩1.60B
Net profit margin
6.23%
Gross margin
39.42%
EBITDA
₩13.31B
Revenue growth
1.26%
Similar securities
This is not an investment recommendation
Ilyang Pharmaceutical for Indian investors
Ilyang Pharmaceutical is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Ilyang Pharmaceutical for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Ilyang Pharmaceutical’s current yield is 1.95%.Dividend tax explained
FAQs
Can I buy Ilyang Pharmaceutical on Paasa?
Ilyang Pharmaceutical (007570) has been listed on the Korea Exchange since 2000, in the Drug Manufacturers - Specialty & Generic industry. Ilyang Pharmaceutical is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Ilyang Pharmaceutical share cost in rupees?
One Ilyang Pharmaceutical share is ₩7,950.00 — about ₹574 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Ilyang Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Ilyang Pharmaceutical shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Ilyang Pharmaceutical price.
Does Ilyang Pharmaceutical pay a dividend, and how is it taxed in India?
Yes. Ilyang Pharmaceutical pays a dividend and the current yield is 1.95%; the last declared dividend was ₩155.00 per share, about ₹11.19. Dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare Ilyang Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Ilyang Pharmaceutical?
Yes. Ilyang Pharmaceutical is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.